Advertising/Labeling Definitions
Q. What is prescription drug advertising?
21 CFR 202.1(l)1 states that advertisements subject to Section 502(n) of the Food, Drug, and Cosmetic Act (FD&C Act) include advertisements published in journals, magazines, other periodicals, and newspapers; and broadcast through media such as radio, television, and telephone communications systems. This is not a comprehensive list of advertising media subject to regulation. For example, FDA also regulates advertising conducted by sales representatives, on computer programs, through fax machines, or on electronic bulletin boards. |
Q. What must a prescription drug advertisement include?
Under section 502(n) of the FD&C Act, advertisements must include: the established name, the brand name (if any), the formula showing quantitatively each ingredient, and information in brief summary which discusses side effects, contraindications, and effectiveness. The brief summary is further discussed in 21 CFR 202.1(e)(1). |
Q. Are there exceptions to the advertising regulations?
Yes, there are a few exceptions but only
to the requirement to provide a true statement of
information in brief summary as required under 21 CFR
202.1(e)(1). 21 CFR 202.1(e)(2) describes which ads are
exempt: 1. Reminder advertisements - advertisements which call attention to the name of the drug product but do not include indications or dosage recommendations for use of the product, or any other representation. Reminder ads contain the proprietary name of the drug and the established name of each active ingredient. They may also contain additional limited information, such as the name of the company, price, or dosage form. The exception does not apply to products with black box warnings in their approved product labeling. 2. Advertisements of Bulk-sale drugs - promote sale of the drug in bulk packages to be processed, manufactured, labeled, or repackaged and that contain no claims for the therapeutic safety or effectiveness of the drug. 3. Advertisements of prescription-compounding drugs - promote sale of a drug for use as a prescription chemical or other compound for use by registered pharmacists. |
Q. What is labeling?
Section 201(m) of the FD&C Act states
labeling ". . . means all labels and other written,
printed, or graphic matter . . . accompanying such
article." The regulations provide examples of labeling under 21 CFR 202.1(l)(2):
|
Q. What must labeling include?
Labeling must include the established name, proprietary name (if any), adequate directions for use, and adequate warnings. The agency considers the approved product labeling, sometimes called the full prescribing information, to be adequate directions for use and adequate warning. |
Q. Are there exceptions to the requirements for labeling?
Yes. Reminder labeling is exempt from the
requirements for adequate directions for use and adequate
warnings. Reminder labeling, as defined in 21 CFR
201.100(f), is exempted. Reminder labeling calls
attention to the name of the drug product but does not
include indications or dosage recommendations for use.
Reminder labeling may contain only the proprietary name
of the drug, the established name of each active
ingredient, and optionally, information relating to
quantitative ingredient statements, dosage form, quantity
of package contents, price, and other limited
information. The exemption does not apply to products with black box warnings in their approved product labeling. |